on MAbxience
MAbxience and Sandoz Join Forces to Enhance Global Access to Biosimilars
mAbxience and Sandoz have formed a collaboration to advance a proposed emicizumab biosimilar for hemophilia A treatment. This agreement combines mAbxience's development and manufacturing prowess with Sandoz's vast commercial network. It aims to enhance patient access to quality biologic medicines worldwide.
Under this partnership, mAbxience will develop and produce the biosimilar in Spain and Argentina. Sandoz will commercialize it globally, except in Argentina, Uruguay, and Paraguay. The financial specifics remain undisclosed. The agreement marks a strategic move as biologic medicines face upcoming patent expirations.
The focus is on expanding into the USD 5.7 billion hemophilia A market. This condition is a prevalent genetic disorder causing defective blood clotting. The collaboration underscores mAbxience's leading role in biosimilar innovation and its commitment to addressing unmet medical needs globally.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAbxience news